The pursuit of market outperformance leads investors to the practice of hand-picking stocks. Skillful choices can be a catalyst for significant wealth enhancement.
In the latest session, Pacific Biosciences of California Inc (NASDAQ: PACB) closed at $2.39 down -9.13% from its previous closing price of $2.63. In other words, the price has decreased by -$9.13 from its previous closing price. On the day, 12.22 million shares were traded. PACB stock price reached its highest trading level at $2.64 during the session, while it also had its lowest trading level at $2.24.
Ratios:
For a deeper understanding of Pacific Biosciences of California Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 5.40 and its Current Ratio is at 6.24. In the meantime, Its Debt-to-Equity ratio is 19.40 whereas as Long-Term Debt/Eq ratio is at 19.38.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Aug 18 ’25 when Van Oene Mark sold 26,836 shares for $1.31 per share. The transaction valued at 35,182 led to the insider holds 1,920,035 shares of the business.
MARK VAN OENE bought 26,836 shares of PACB for $35,174 on Aug 18 ’25. On May 19 ’25, another insider, Farmer Michele, who serves as the insider of the company, sold 5,195 shares for $1.00 each. As a result, the insider received 5,200 and left with 269,259 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, PACB now has a Market Capitalization of 721558784 and an Enterprise Value of 1125984768. For the stock, the TTM Price-to-Sale (P/S) ratio is 4.67 while its Price-to-Book (P/B) ratio in mrq is 19.99. Its current Enterprise Value per Revenue stands at 7.284 whereas that against EBITDA is -5.846.
Stock Price History:
The Beta on a monthly basis for PACB is 2.29, which has changed by 0.25130892 over the last 52 weeks, in comparison to a change of 0.12934029 over the same period for the S&P500. Over the past 52 weeks, PACB has reached a high of $2.72, while it has fallen to a 52-week low of $0.85. The 50-Day Moving Average of the stock is 38.46%, while the 200-Day Moving Average is calculated to be 71.18%.
Shares Statistics:
For the past three months, PACB has traded an average of 8.38M shares per day and 10840610 over the past ten days. A total of 301.85M shares are outstanding, with a floating share count of 270.83M. Insiders hold about 10.29% of the company’s shares, while institutions hold 52.61% stake in the company. Shares short for PACB as of 1763078400 were 33569699 with a Short Ratio of 4.01, compared to 1760486400 on 34508178. Therefore, it implies a Short% of Shares Outstanding of 33569699 and a Short% of Float of 12.640001000000002.
Earnings Estimates
Current recommendations for the stock of the company come from 9.0 analysts. The consensus estimate for the next quarter is -$0.12, with high estimates of -$0.09 and low estimates of -$0.14.
Analysts are recommending an EPS of between -$0.53 and -$0.56 for the fiscal current year, implying an average EPS of -$0.54. EPS for the following year is -$0.47, with 8.0 analysts recommending between -$0.31 and -$0.54.
Revenue Estimates
A total of 8 analysts believe the company’s revenue will be $41.82M this quarter.It ranges from a high estimate of $43M to a low estimate of $40.4M. As of. The current estimate, Pacific Biosciences of California Inc’s year-ago sales were $39.22MFor the next quarter, 8 analysts are estimating revenue of $41.31M. There is a high estimate of $44M for the next quarter, whereas the lowest estimate is $38.7M.
A total of 9 analysts have provided revenue estimates for PACB’s current fiscal year. The highest revenue estimate was $158.17M, while the lowest revenue estimate was $155.8M, resulting in an average revenue estimate of $157.17M. In the same quarter a year ago, actual revenue was $154.01MBased on 9 analysts’ estimates, the company’s revenue will be $176.54M in the next fiscal year. The high estimate is $184.6M and the low estimate is $165.2M.
